Synthetic biology’s first malaria drug meets market resistance

Mark Peplow

Nature, 2016, vol. 530, issue 7591, 389-390

Abstract: Commercial use of genetically engineered yeast to make medicine has modest impact.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/530390a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:530:y:2016:i:7591:d:10.1038_530390a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/530390a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().